Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Metropole Savoie
About this trial
The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers.
The main question it aims to answer is :
Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment?
The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.
Eligibility criteria
Qualifiers
Patients over 18 years old
Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment.
CT/PET performed within 45 days before initiation of systemic treatment.
Patient able to sign informed consent for participation in the study
Disqualifiers
History of cancer in the five years preceding inclusion other than localized skin or cervical cancers.
Patient with cancer not requiring systemic treatment.
Pregnant women.
Patient with a pace maker or defibrillator
Trial design
Treatments tested in this trial
- Sarcopenia diagnostic test
Treatment groups
700 Participants
are divided into 1 treatment groupSponsors and collaborators
Centre Hospitalier Metropole Savoie
Lead sponsor
Université Savoie Mont Blanc
Collaborator
Source ClinicalTrials.gov